Compare BFS & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | IRWD |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.1M | 663.6M |
| IPO Year | N/A | 2009 |
| Metric | BFS | IRWD |
|---|---|---|
| Price | $34.26 | $4.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $44.00 | $7.67 |
| AVG Volume (30 Days) | 43.8K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $0.30 | $57.95 |
| Revenue Next Year | $5.67 | $4.39 |
| P/E Ratio | $30.48 | ★ $27.77 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $29.16 | $0.55 |
| 52 Week High | $35.45 | $5.78 |
| Indicator | BFS | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 60.37 |
| Support Level | $32.42 | $3.80 |
| Resistance Level | $34.94 | $4.50 |
| Average True Range (ATR) | 0.63 | 0.26 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 68.56 | 82.69 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.